SOCRA Knowledge 1 — Questions and Answers
Question 1: Which of the following is a disclosure of financial interests form?
- 21 Cfr 312
- 3500, Fda 3500
- Form 3454
- FDA Form 3455 (Correct answer)
Correct answer: FDA Form 3455
FDA Form 3455 is the correct form for disclosing financial interests in clinical research. This form is mandated by 21 CFR Part 54 and requires clinical investigators to report any financial arrangements that could potentially influence the outcome of a study. Its use helps ensure transparency and mitigate conflicts of interest in clinical trials.
Question 2: The form ___ is used for investigational new drugs (or IND)
- 1571 (Correct answer)
- 1572
- 3500a
- 1583
Correct answer: 1571
FDA Form 1571, titled 'Investigational New Drug Application (IND) – Sponsor,' is the primary form used to submit an Investigational New Drug Application to the FDA. This form initiates the process for a sponsor to seek permission to test a new drug in human subjects. It serves as the cover sheet and summary for the comprehensive IND submission.
Question 3: Which of the following is 21 CFR 56.106 Subpart B?
- Certification
- Licensure
- Fda Form 3455
- Registration (Correct answer)
Correct answer: Registration
21 CFR 56.106, found within Subpart B, specifically addresses the 'Registration' requirements for Institutional Review Boards (IRBs). This regulation mandates that IRBs that review FDA-regulated research must register with the FDA. This registration process helps the FDA track and oversee IRBs to ensure they meet regulatory standards for protecting human subjects.
Question 4: What is 21 CFR 50.27?
- Exception from general requirements
- Documentation of informed consent (Correct answer)
- Hhs - protection of human health subjects
- Irb review of research
Correct answer: Documentation of informed consent
21 CFR 50.27 specifically details the 'Documentation of Informed Consent' requirements. This section outlines how informed consent must be recorded, typically through a written consent form signed and dated by the subject or their legally authorized representative. It ensures that there is a clear record that the informed consent process was properly conducted and documented.
Question 5: _________ means the party who submits a marketing application to FDA for approval of a drug device or biologic product.
- Contract Research Organization
- Authors Of Similar Models
- The Sponsor
- Clinical Investigator (Correct answer)
Correct answer: Clinical Investigator
While typically the 'Sponsor' is the entity that submits a marketing application to the FDA, in certain cases, an individual clinical investigator may also act as a 'Sponsor-Investigator.' A Sponsor-Investigator initiates and conducts an investigation and also takes on the responsibilities of a sponsor. In this specific scenario, the clinical investigator would be the party responsible for submitting the marketing application for approval of a drug, device, or biologic product.
Question 6: The responsibility for ensuring that the investigator understands a clinical trial lies with which individual/or organization?
- FDA
- IRB
- Sponsor (Correct answer)
- Coordinator
Correct answer: Sponsor
The sponsor of a clinical trial holds the ultimate responsibility for ensuring that the investigator understands the clinical trial protocol and their obligations. This includes providing comprehensive training, clear study documents, and ongoing support to the investigator. The sponsor's oversight is crucial for maintaining the integrity of the study and protecting the rights and safety of subjects.
Question 7: What is the minimum number of IRB members?
- 3
- 5 (Correct answer)
- 6
- 10
Correct answer: 5
According to FDA regulations (21 CFR 56.107), an Institutional Review Board (IRB) must have at least five members. This minimum number ensures a diverse range of expertise and perspectives are present during the review of research protocols. A larger, diverse committee helps to provide a thorough and unbiased ethical and scientific review of studies involving human subjects.
Question 8: In a non-emergency situation, under which of the following conditions, if any, may subjects been rolled into a study prior to IRB/IEC approval?
- A majority of the members'primary area of interest is in a scientific area
- At least one member holds a Ph.D. degree or equivalent
- At least one member's primary area of interest is in a nonscientific area (Correct answer)
- A majority of the members are from or have ties to the institution of record
Correct answer: At least one member's primary area of interest is in a nonscientific area
For an IRB to be properly constituted and capable of reviewing research, it must include at least one member whose primary area of interest is in a nonscientific area. This requirement ensures that the IRB considers the perspectives of the general public and non-scientific ethical concerns, balancing scientific rigor with broader societal values. This diversity helps ensure a comprehensive ethical review of research.
Question 9: A purpose of monitoring clinical trials is to verify that:
- The rights, safety, and well-being of human subjects are protected (Correct answer)
- Investigators receive adequate payment for their participation in the clinical trial
- The investigator has received annual reports from the sponsor
- The regulatory agency has received all case history information of subjects enrolled on the clinical trial
Correct answer: The rights, safety, and well-being of human subjects are protected
A primary purpose of monitoring clinical trials is to verify that the rights, safety, and well-being of human subjects are protected. Monitors regularly visit study sites to ensure adherence to the protocol, Good Clinical Practice (GCP), and regulatory requirements. This oversight helps identify and address any issues that could compromise subject safety or ethical conduct.
Question 10: Which of the following is the proper way to make a correction to a CRF?
- Completely blacken the incorrect entry and then enter the correct information
- Back date the corrected entry with the date of the original entry
- Initial using the initials of the sponsor's representative who reviewed the change
- Add the initials of the person making the change, the date of the change, and , if necessary, a brief explanation of the change (Correct answer)
Correct answer: Add the initials of the person making the change, the date of the change, and , if necessary, a brief explanation of the change
When making corrections to a Case Report Form (CRF), the proper procedure is to draw a single line through the incorrect entry, ensuring the original entry remains legible. Then, the correct information should be written next to it, followed by the initials of the person making the change, the date of the change, and a brief explanation if necessary. This method maintains an audit trail and ensures data integrity.
Question 11: The clinical investigator will update the financial disclosure information if any relevant changes occur during the investigation's course and for _______ following the study's completion.
- 6 months
- 1 year (Correct answer)
- 2 years
- 5 years
Correct answer: 1 year
Clinical investigators are required to update their financial disclosure information if any relevant changes occur during the course of the investigation. Furthermore, this disclosure must be maintained and updated for at least one year following the study's completion. This ongoing requirement ensures transparency regarding potential conflicts of interest even after the trial concludes.
SOCRA Knowledge 1
Which of the following is a disclosure of financial interests form?